RxDoctor Payments Data

Jai Abraham

Acute Care · Plano, TXNPI 1336457662

Payments from drug & device makers

$3,412in general payments, 2019–2025

Across 118 payments — averaging $28.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Sanofi-aventis U.S. LLC$364
  • Johnson & Johnson$332
  • Pfizer$326
  • Itamar Medical Inc$276
  • E.r. Squibb & Sons, L.L.C.$164
  • plus $890 from 15 others

What the payments were for

  • Food & beverage$3,29497%
  • Education$1043%
  • Entertainment$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,412 in reported general payments places this provider in the 90th percentile of 2,323 acute care providers in Texas.

See all acute care providers in Texas

Medicare billing

Part B allowed, 2024
$141,513
Medicare patients
693
Services billed
2,652

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban315$400,176
XareltoRivaroxaban66$96,918
MultaqDronedarone Hcl23$40,793
Dofetilide136$22,908
Metoprolol Succinate305$5,338
Flecainide Acetate128$4,802
Mexiletine Hcl33$2,501
SotalolSotalol Hcl64$1,425
Amiodarone Hcl87$1,411
Diltiazem 24hr ErDiltiazem Hcl24$725
Metoprolol Tartrate142$683
Diltiazem 24hr Er (Cd)Diltiazem Hcl14$537
Diltiazem Hcl13$337
Carvedilol23$198

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$326$400,176315 claims
Johnson & JohnsonXarelto$332$96,91866 claims
Sanofi-aventis U.S. LLCMultaq$364$40,79323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,323 acute care providers in Texas.

Other acute care in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →